19-20 February, 2019 | San Diego, CA

Day One
Tuesday, January 30, 2018

Day Two
Wednesday, January 31, 2018

08.20
Chairs’ Opening Remarks


Applying Liquid Biopsy for the Advancement of Precision Medicine

08.30
The Whole Transcriptional Landscape of Circulating Tumor Cells Compared to Metastases in Stage IV Breast Cancer

Synopsis

  • Better understanding of CTC-biology compared to metastasis may shed light on treatment opportunities and help advance the application of CTCs as liquid biopsies in clinical practice
  • Demonstrating the feasibility of gene expression profiling of rare CTCs
  • Evaluating whether whole transcriptome sequencing (RNA Seq) gene expression profiling of ANGLE Parsortix isolated CTCs may serve as a surrogate for biopsies of macro metastases

09.00
The Liquid Biopsy State of Play: From Prognostic to Predictive

Synopsis

  • Where do we currently stand with the clinical impact of liquid biopsy on the delivery of personalized care?
  • Analyzing the application of liquid biopsy for longitudinal disease monitoring to inform resistance, treatment selection and disease recurrence
  • Discussing the evolution of liquid biopsy testing towards a future of early detection and screening of prodromal populations
  • How far have we come, and what do we need to do, in order to continue the integration of liquid biopsies into the precision medicine paradigm?

09.25
Harnessing Liquid Biopsy Testing for Precision Medicine Patient Selection

Synopsis

  • Utilizing circulating biomarkers as clinical research tools to produce novel predictive biomarker signatures
  • Understanding how liquid biopsies can add another dimension to the robust selection of patient responders for targeted therapeutics
  • Discussing the route for bridging liquid biopsy patient selection assays to IDEs for pivotal clinical studies

09.50
Session Q&A

Synopsis

  • Q&A with the sessions speakers
  • Beyond NSCLC, where are we seeing benefit from the us of liquid biopsy and how do we advance the clinical utility of testing in such indications?
  • Despite all the investment and innovation in precision medicine we are still prognostic in our use, how do we get to a place where we are getting predictive utility?
  • What will the precision medicine field look like over the next 5-10 years with the fast developing applications of liquid biopsies?

10.35
Speed Networking & Morning Refreshments


Evaluating the Scope of Clinical Utility for Circulating Biomarkers

11.20
Analyzing the Clinical Impact of ctDNA Based Testing

Synopsis

  •  Dissecting clinical utility: Is there a limit on how impactful a clinical decision can be made from ctDNA based testing?
  • Validating the impact of ctDNA testing on the accuracy of clinical decision: What’s real, what’s technical, what’s just tumor heterogeneity?

11.45
Multigene Blood mRNA Signatures for Diagnosis and Therapeutic Monitoring of Myeloma, Melanoma, Colon, Prostate, Neuroendocrine Gut and Lung tumors

Synopsis

  • Blood Transcript analysis demonstrates high sensitivity and specificity as a diagnostic tool
  • Stratifies patients into stable and progressive disease groups
  • Functions as a complementary diagnostic/ predictor signature for the efficacy of a specific drug or isotope therapy
  • Monitors treatment efficacy and identifies the risk of disease progression and treatment failure
  • Confirms complete resection and identifies minimum residual disease post-therapy or surgery

12.00
Evaluating the Evolving Use of Circulating Tumor Cells for Liquid Biopsy

Synopsis

  • Addressing phenotypic heterogeneity of CTCs and their effectiveness for prognostic clinical monitoring
  • Evolving sampling detection of circulating tumor cells to improve sensitivity of testing

12.25
Lunch & Networking

13.25
The Clinical Application of CXCR4 Expression on Tumor and Circulating Tumor Cells as a Potential Prognostic and Predictive Response Marker in Extensive-Disease Small Cell Lung Cancer

Synopsis

  • Exploratory analyses evaluated CXCR4 expression on available baseline tumor tissue and on circulating tumor cells (CTCs) collected at baseline in patients with extensive disease small cell lung cancer (ED-SCLC).
  • Patients with ED-SCLC were treated with either standard of care etoposide/carboplatin (CE) or CE+LY2510924.
  • Baseline CXCR4 expression in tumor tissue and on CTCs was explored for the potential to be prognostic of survival or predictive of LY2510924 treatment response

13.50
Getting Closer to the Site of Action: Extracellular Vesicles as Biomarkers for Cancer Immunotherapy Drug Development

Synopsis

  • Evaluating the scope for the clinical applicability of extracellular vesicles as circulating biomarkers
  • Building the methodology and technical expertise for fluid based extracellular vesicle testing

14.15
Exploiting Extracellular Body Fluid RNA for Precision Medicine Purposes

Synopsis

  • Discussing various workflows for RNA sequencing of body fluid derived RNA, including probe based target capture as a sensitive RNA sequencing workflow to study thousands of mRNA and lncRNA genes in cell-free RNA from cancer patients’ plasma and urine
  • Debating the pre-analytical jungle of RNA targeted liquid biopsies and need for standardization, as part of the ongoing exRNAQC study

14.40
Session Q&A

Synopsis

  • Q&A with the sessions speakers
  • Where does the most clinical value lie for liquid biopsies?
  • Evaluating the pros and cons of circulating biomarkers and their attribution across disease indications

15.25
Afternoon Refreshments


Standardization and Validation: The Challenges Associated with Establishing Accuracy of Liquid Biopsy Assays

15.45
Improving Sensitivity and Accuracy While Reducing Cost: HRM Enables Rapid Mutation Assessment Prior to Targeted Re-Sequencing

Synopsis

  • Discussing novel forms of real time PCR that reduce the effort for sample preparation while also providing rapid assessment of mutation status prior to targeted resequencing
  • Discussing implementation of mutation enrichment via COLD-PCR or NaME-PrO together with high resolution melting
  • Highly sensitive detection of micro-satellite instability in plasma as a unique application
  • Application in circulating DNA from clinical cancer samples will be presented

16.10
Product Development Updates for Liquid Biopsy Reference Standards

Synopsis

  • Additional information to follow

16.20
Super Selective Primers for Multiplex Real-time PCR Assays that Assess the Abundance of Rare Mutations Associated with Cancer

Synopsis

  • “SuperSelective” PCR primers, due to their unique design, are extraordinarily specific, able to selectively initiate the synthesis of amplicons on ten mutant DNA fragments in the presence of 1,000,000 wild-type DNA fragments
  • Sets of SuperSelective primers, each possessing unique 5’-tag sequences, enable the amplicons generated from each mutant to be distinguished by differently colored molecular beacon probes
  • Inclusion of primers for a wild-type reference gene enables the abundance of each type of mutant DNA fragment to be assessed by determining the difference between its threshold value and the threshold value of the reference gene

16.45
Session Q&A

Synopsis

  • Q&A with the sessions speakers
  • In such a dynamic, multi-stakeholder industry, how can we work together to derive a level of standardization and validation across the field?
  • Debating the improvement in the sharing of data, particularly for LDTs, for test validation and standard comparison
  • Discussing the challenges of validation, the best materials and controls to use the and best approaches for robust validation
  • Developing standards for downstream bioinformatics: How do we or can we unify research, academic and commercial lab processes?
  • Discussing the lack of adequate reference materials (both positive and negative),what does one use as a “gold standard” reference method to compare against?
  • Standardizing terms: Aligning metrics and endpoints for analytical performance to truly assess assay capabilities
  • Debating trade-offs between assay technology and ultimately from a physician’s perspective, what is most important?

17.30
Chairs’ Closing Remarks

17.35
End of Day One